Segall Bryant & Hamill LLC Buys 13,253 Shares of Repligen Corporation (NASDAQ:RGEN)

Segall Bryant & Hamill LLC boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 10.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 145,396 shares of the biotechnology company's stock after purchasing an additional 13,253 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.26% of Repligen worth $18,500,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Utah Retirement Systems increased its stake in shares of Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after buying an additional 100 shares during the last quarter. State of Michigan Retirement System grew its holdings in Repligen by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after buying an additional 100 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock worth $1,858,000 after purchasing an additional 100 shares in the last quarter. Peapack Gladstone Financial Corp boosted its holdings in shares of Repligen by 5.2% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock valued at $301,000 after acquiring an additional 103 shares in the last quarter. Finally, Signaturefd LLC boosted its stake in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Up 3.6%

Repligen stock traded up $4.29 during mid-day trading on Thursday, reaching $124.04. The company's stock had a trading volume of 582,585 shares, compared to its average volume of 726,948. The company has a market capitalization of $6.97 billion, a price-to-earnings ratio of -275.64, a price-to-earnings-growth ratio of 3.43 and a beta of 1.11. The business's 50 day simple moving average is $124.79 and its 200 day simple moving average is $138.70. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a 12 month low of $102.97 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same quarter last year, the company posted $0.28 earnings per share. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. As a group, research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. HC Wainwright restated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research note on Monday, May 5th. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Royal Bank Of Canada dropped their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group dropped their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $170.75.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.